查看文章

In the last decade, there has been an upsurge of health technology assessments (HTAs) and corresponding bodies producing, judging and disseminating such assessments. Notably in the area of clinical pharmacology, HTAs have become a prerequisite before widespread clinical use of pharmacotherapies in Western countries can be considered. In particular, HTAs use evidence-based medicine techniques and provides a toolkit (often in the framework of reimbursement decisions) comprising of criteria, standards, procedures and guidance for use in practice [101]. Application of HTAs leads to reimbursement decisions in countries such as The Netherlands, Belgium and Sweden and guidance on use in the UK as provided by the NICE for England and Wales and the Scottish Medicines Consortium. Health technology assessments have proven to be very useful in analyzing new innovative pharmacotherapies at the …